Proinsulin-Predominant Pancreatic Neuroendocrine Tumor-Induced Hypoglycemia After ROUX-EN-Y Gastric Bypass Surgery

• Main Authors: Khary Edwards, MD, Lori de La Portilla, DO, Faryal S. Mirza, MD, Pooja Luthra, MD
• Format: Article
• Language: English
• Published: Elsevier 2019-11-01
• Series: AACE Clinical Case Reports
• Online Access: http://www.sciencedirect.com/science/article/pii/S2376060520300316

ABSTRACT: Objective: To present a case of recurrent hypoglycemia following Roux-en-Y gastric bypass (RYGB) surgery whose etiology was determined to be a proinsulin-predominant pancreatic neuroendocrine tumor (a proinsulinoma). Methods: A case report along with a brief discussion and review of the pertinent literature is presented. Results: The patient is a 62-year-old female who presented with symptomatic hypoglycemia 11 years after RYGB surgery. Initial workup revealed low insulin levels with elevated proinsulin levels. A 72-hour fast confirmed the presence of proinsulin-induced hypoglycemia secondary to a pancreatic neuroendocrine tumor (PNET). She underwent distal pancreatectomy with splenectomy and a PNET tumor was successfully removed with resolution of her symptoms. Conclusion: Hypoglycemia after RYGB surgery is a well-established syndrome. While there are several etiologies for this, PNETs (including proinsulinomas) should be considered in the differential diagnosis in this population. Proinsulinomas are an increasingly recognized cause of hypoglycemia. Proinsulin levels must always be included as part of the workup of hypoglycemia in an adult.